Is TRDA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for TRDA. It does not provide personalized investment advice.

TRDA (Entrada Therapeutics, Inc. Common Stock) Stock Analysis - Financials

Entrada Therapeutics, Inc. Common Stock (TRDA) is a publicly traded Healthcare sector company. As of September 10, 2026, TRDA trades at $7.12 with a market cap of $292.80M and a P/E ratio of -1.81. TRDA moved -5.45% today. Year to date, TRDA is -30.84%; over the trailing twelve months it is +38.33%. Its 52-week range spans $4.93 to $16.45. Analyst consensus is strong buy with an average price target of $17.00. Rallies surfaces TRDA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are TRDA's key financials?

TRDA financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. TRDA recently traded at $7.12. Market cap is $292.80M. P/E ratio is -1.81. Revenue is $4.69M.

TRDA Key Metrics

Key financial metrics for TRDA
Metric	Value
Price	$7.12
Market Cap	$292.80M
P/E Ratio	-1.81
EPS	$-3.96
Dividend Yield	0.00%
52-Week High	$16.45
52-Week Low	$4.93
Volume	332.00K
Avg Volume	0
Revenue (TTM)	$4.69M
Net Income	$-165.78M
Gross Margin	0.00%

TRDA Analyst Consensus

4 analysts cover TRDA: 0 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $17.00.

Common questions about TRDA

What are TRDA's key financials?: TRDA financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. TRDA recently traded at $7.12. Market cap is $292.80M. P/E ratio is -1.81. Revenue is $4.69M.
Is TRDA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for TRDA. It does not provide personalized investment advice.